This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Cyclin-dependent kinase 4 (CDK4); cyclin D1 (CCND1; BCL1)	The crystal structure of the CDK4-CCND1 complex could help identify new CDK4 inhibitors to treat cancer. The structure revealed an intermediate conformation different from those previously described for other CDK-cyclin complexes, thus providing new possibilities for the rational design of CDK4 inhibitors. Such work is ongoing under a cell-cycle inhibitor collaboration between Astex Therapeutics Ltd. and Novartis AG. Onyx Pharmaceuticals Inc. and Pfizer Inc. are running a Phase I trial of the CDK4 inhibitor PD 332991 to treat cancer.	Patent status undisclosed; structure licensed to Novartis worldwide; unavailable for licensing	Dat, P. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Feb. 16, 2009; doi:10.1073/pnas.0809645106 Contact: Harren Jhoti, Astex Therapeutics Ltd., Cambridge, U.K. e-mail: h.jhoti@astex-therapeutics.com
SciBX 2(7); doi:10.1038/scibx.2009.264 Published online Feb. 19, 2009				